Skip to content

Study · Randomized controlled trial · n = 8 · 2024

1 result

Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.

Herfarth H, Herfarth H, Long MD, Hansen JJ, Anderson C, English E, Buse JB, Barnes EL

The American journal of gastroenterology12 Apr 2024Cited by 3 (Europe PMC)

PMID38668926 (opens in a new tab)PMCIDPMC11365596 (opens in a new tab)DOI10.14309/ajg.0000000000002801 (opens in a new tab)PepBankPUB-38668926
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with an ileal pouch-anal anastomosis and refractory high bowel frequency, liraglutide, but not placebo, reduced daily bowel frequency by more than 35%.

    In plain wordsIn patients with a surgical ileal pouch and frequent bowel movements, liraglutide reduced daily bowel movements, but placebo did not.

    Peptide
    Liraglutide
    Outcome
    DecreaseDaily bowel frequency
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Reduction in daily bowel frequency
    > 35%
    liraglutide

    Source sentences

    Summary
    Liraglutide, but not placebo, reduced daily BF by more than 35% ( P < 0.03).
    1 context sentence
    Summary · context
    Double-blind crossover study of 8 IPAA patients with refractory high BF treated with daily administration of the GLP-1 receptor agonist liraglutide or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07756359

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

University of North Carolina, Chapel Hilln = 20est. Sept 2026 to est. Sept 2027

Pouch, Ileal · Pouches, Ileoanal · Bowel Diseases, Inflammatory

Trial pageClinicalTrials.govUpdated 10 Aug 2026
TerminatedPhase 2Results postedNCT04763564

Efficacy of Liraglutide Therapy in Patients With IPAA

University of North Carolina, Chapel Hilln = 822 Mar 2022 to 16 Oct 2023

Pouchitis · Irritable Pouch Syndrome

Trial pageClinicalTrials.govUpdated 23 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.